Clinical Trial 49939

Phoenix, AZ 85013


The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1b clinical trial to evaluate AZD1390 in patients with recurrent WHO grade IV glioma.

The goal of Phase 0  is to confirm that AZD1390 is capable of crossing the blood-brain barrier. Patients with positive results may advance to the 1b expansion phase which combines therapeutic dosing of AZD1390 with standard-of-care fractionated radiotherapy.

The expansion phase will examine progression-free survival and monitor safety and tolerability of AZD1390 in combination with radiation.

  • AZD1390 is a highly potent brain penetrant ATM (Ataxia telangiectasia mutant) kinase inhibitor that blocks the repair of DNA breaks caused by radiation treatment. 
  • AZD1390 is in early clinical development for use as a radiosensitizer in central nervous system malignancies.
  • Radiosensitizers  make tumor cells more vulnerable to radiation therapy.
  • You are 18 years or older.
  • You have had prior resection (surgical removal) of a diagnosed 2021 WHO grade IV glioma and followed standard therapy, including temozolomide and fractionated radiotherapy.
  • Your doctor has told you that your tumor has recurred (come back) or has progressed (grown or changed) and you require resection with radiation therapy as part of your post-surgical treatment plan.

Qualified Participants May Receive:

As part of a clinical trial at the Ivy Brain Tumor Center, the study drugs will be provided free of charge, however, the patient and/or their health plan/insurance company will be responsible for some or all of the costs of treating the tumor in the study, including any standard medical care such as surgical resection.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.